comprehensive -WSS

comprehensive

author：comprehensive 2025-09-03 09:19:11 - browse：48974

Illustration of a crowd of people looking toward a cityscape. — Adobe

Few public health challenges have been more daunting and persistent than the opioid crisis, which started because of egregious conduct by opioid manufacturers and now is driven by an influx of fentanyl. In my home state of New Hampshire — which has been at the forefront of this heartbreaking epidemic for more than a decade — too many promising futures have been snatched away. As we look to the next stage of bipartisan efforts to take on this challenge, we must quickly reauthorize and expand the SUPPORT Act, which expired Sept. 30. It laid a new foundation for our response to this epidemic — and now it can be used to increase access to the gold standard of treatment for addiction.

In 2018, we came together across party lines to pass the SUPPORT Act, which established vital infrastructure for communities in New Hampshire and across the country to treat addiction, help people recover, and prevent substance misuse in the first place.

While there are dozens of vital measures in this legislation, one of the most critical provisions helped expand access to medication-assisted treatment, the gold standard of addiction care. Access to this lifesaving medication, buprenorphine, has historically been limited by law and clinician reluctance, fueled by harmful stigmas surrounding addiction treatment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： R1 RCM gets $5.8 billion buyout offer from private equity firm

WSS

The drug industry has found itself all alone in Washington

With psoriasis trial ahead, Alumis raises $259 million

With psoriasis trial ahead, Alumis raises $259 million

In utero gene editing: an explainer

RSV shot was 90% effective at preventing hospitalizations in kids

Ed Silverman on new gene therapies, biosimilars, coffee, and more

focus

comprehensive

entertainment

Psychedelics group wrestles with new pharma identity

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Affirmative action in medical school literally saved lives

Headspace, Meta partner to launch VR meditation app for Quest

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NIH study of ME/CFS points to clear biological hallmarks

What does generative AI mean for health care? We asked experts

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Sports medicine is finally prioritizing gender equality

Amylyx ALS drug failure raises questions and concerns

leisure time

Former medical device CEO who sold dummy, plastic parts convicted of fraud

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Alabama hospital puts IVF treatments on hold

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

The drug industry has found itself all alone in Washington

focus

hotspot

entertainment

hotspot